NCT06546488Recruiting

Cognitive Assessment Tools for Huntington's Disease.

Ohio State University

Start Date

6/20/2025

Completion Date

12/1/2027

Summary

The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the Self-Administered Gerocognitive Examination (SAGE). Both the Coding Test and the SAGE have been used for assessments of individuals with other neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease and Lewy Body Disease, but data is lacking on their use in individuals with HD.

Detailed Description

Subjects will be recruited from the OSU Wexner Medical Center Huntington Society of America Center of Excellence Clinic. Subjects will be scheduled for a one-time visit to complete the study. The entire visit will take approximately 1-1.5 hours. Vital signs (weight, blood pressure, temperature, respiratory rate and pulse) will be conducted. The subject's medical records will be reviewed to obtain their demographics, current medications, medical/surgical/ HD family history, and HD diagnosis details. If any adverse events occur during the research visit they will be documented. Participants will complete cognitive, functional and motor assessments.

Eligibility Criteria

Age Range: 30 years to 65 years

Inclusion Criteria: 1. Males and females aged 30-65 (inclusive) at the time of signing the informed consent form. 2. Genetic diagnosis of HD as defined by a CAG repeat size ≥ 40. 3. A clinical diagnosis of HD as defined by a Diagnostic Confidence Level (DCL) of 4. 4. Vision and hearing sufficient for compliance with tests. 5. On a stable dose of medications for 30 days prior to the time of signing the informed consent form. Exclusion Criteria: 1. Age of symptom onset less than 19 years old or greater than 60 years old. 2. Any serious neurological disorder aside from HD, including but not limited to Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Lewy body dementia, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury… etc. that in the opinion of the investigator is clinically significant. 3. Any ongoing serious medical condition that in the opinion of the investigator is clinically significant. This includes autoimmune diseases, ongoing treatment for cancer, congestive heart failure, severe pulmonary disease, or any history of a seizure disorder (including the need to take anti-epileptics to prevent seizure). 4. Subjects who are pregnant or breast feeding 5. Subjects with a history of a learning disability. 6. Subjects who are unable to provide consent.

Interventions

BEHAVIORAL

Assessments

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Huntington Disease

Locations

The Ohio State University Wexner Medical Center

Columbus, Ohio 43221

United States